October 9, 2016
New Data on the Combination of Lilly’s ALIMTA and Merck’s KEYTRUDA
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: oncology
February 17, 2016
Durvalumab granted BTD by FDA for cancer patients
AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.
January 29, 2016
Charterhouse begins groundwork for $700 million-plus Doc Generici sale -sources
By Pamela Barbaglia LONDON (Reuters) – European buyout firm Charterhouse [CHCAP.UL] is preparing for the sale of its Italian generic…
January 5, 2016
Midatech in vaccines collaboration with Emergex
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has entered into a licensing agreement with Emergex Vaccines Limited, a private UK biotechnology company focused on infectious diseases utilising Midatech’s gold nanoparticle technology.
December 30, 2015
Midatech closes deal on acquiring Zuplenz
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
December 17, 2015
Bristol’s drug pricing under fire as UK agency rejects Opdivo
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
December 15, 2015
BMS and UCLA conjoin oncology research program
Bristol-Myers Squibb has entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
December 1, 2015
Frances Neovacs engaging in immuno-oncology
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board
November 27, 2015
No revenues for Kiadis Pharma in the first 9 months 2015
Kiadis Pharma did not generate any revenues in the first nine months of 2015, the company said Friday.